Document is current
Any future updates will be listed below
-
Authors
Duru, Ilhan Cem
Lecomte, Alexandre
Laine, Pia
Shishido, Tânia Keiko
Suppula, Joni
Paulin, Lars
Scheperjans, Filip
Pereira, Pedro A. B.
Auvinen, Petri
-
Funding
Funding for this research was provided by:
Novo Nordisk Foundation (NNF22OC0080109)
Academy of Finland
- License Information
-
More Information
Article History
Received: 18 April 2024
Accepted: 1 April 2025
First Online: 21 April 2025
Declarations
:
: F.S. received grants from the Academy of Finland, the Hospital District of Helsinki and Uusimaa, the OLVI Foundation, Konung Gustaf V:s och Drottning Victorias Frimurarestiftelse, the Wilhelm and Else Stockmann Foundation, the Emil Aaltonen Foundation, the Yrjö Jahnsson Foundation and the Sigrid Jusélius Foundation, Renishaw. Honoraria: AbbVie, Axial Biotherapeutics, Orion, GE Healthcare, Merck, Teva, Bristol Myers Squibb, Sanofi, Biocodex, Lundbeck, and Biogen. FS is the founder and CEO of NeuroInnovation Oy and NeuroBiome Ltd. and is a member of the advisory boards of Axial Biotherapeutics and MRM Health. He has stock options from Axial Biotherapeutics. P.A.B.P., L.P., P.A., and F.S. have patents issued (FI127671B, US10139408B2, US11499971B2) and pending (US16/186,663, EP3149205) that are assigned to NeuroBiome Ltd. T.K.S. was funded by the Novo Nordisk Foundation (NNF22OC0080109). The rest of the authors (I.C.D, A.L., P.L, and J.S) declare no competing interests.
